Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0718 in moderate to severe Atopic Dermatitis
NCT06477835Phase 3Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rademikibart in atopic dermatitis (AD), sponsored by Simcere Pharmaceutical Group. Started Jul 2024; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06477835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477835.